SOHO 2021: amyloidosis treatment updates
Over the last two decades the outcomes of patients with amyloidosis have substantially improved with timely diagnosis, the use of…
Date: 30th September 2021
IACH 2021: CAR-T in clinical practice
Currently, five chimeric antigen receptor T-cell (CAR-T) therapies are approved for the treatment of hematological malignancies including acute lymphoblastic leukemia,…
Date: 30th September 2021
SOHO 2021: amyloidosis treatment updates
Over the last two decades the outcomes of patients with amyloidosis have substantially improved with timely diagnosis, the use of…
Date: 30th September 2021
IACH 2021: CAR-T in clinical practice
Currently, five chimeric antigen receptor T-cell (CAR-T) therapies are approved for the treatment of hematological malignancies including acute lymphoblastic leukemia,…
Date: 30th September 2021
Unmet needs and recent updates in CML
The treatment of chronic myeloid leukemia (CML) has substantially evolved since the FDA approval of the tyrosine kinase inhibitor imatinib…
Date: 29th September 2021
IMW 2021: treatment-free intervals in multiple myeloma
Continuous therapy has been a key aspect of the standard of care approaches for the treatment of multiple myeloma for…
Date: 29th September 2021
Highlights from iwCLL 2021
The management of chronic lymphocytic leukemia (CLL) has evolved drastically over the last few years, with the introduction of novel…
Date: 27th September 2021
IMW 2021: MRD in myeloma
Measurable residual disease (MRD) is emerging as an important prognostic marker in the management of multiple myeloma. Promising clinical evidence…
Date: 20th September 2021
CAR-T vs bispecifics: replacing ASCT in myeloma
Autologous stem cell transplantation (ASCT) has been the standard of care patients with multiple myeloma for the past three decades;…
Date: 17th September 2021
EHA 2021: antibody therapies for NHL
Antibody therapies are rapidly transforming the treatment landscape of non-Hodgkin lymphoma (NHL). Since the development of rituximab as an anti-CD20…
Date: 10th September 2021
EHA 2021: updates on novel agents for AML
A significant number of patients with acute myeloid leukemia (AML) are unable to withstand intensive chemotherapy regimens due to older…
Date: 8th September 2021
Texas MPN Workshop 2021: updates on JAK inhibitors for MPNs
Janus kinase (JAK) inhibitors are becoming an increasingly prominent class of drug in the treatment of myeloproliferative neoplasms (MPNs), in…
Date: 3rd September 2021
EHA 2021: targeted therapies for ALL
Great progress has been made in the treatment of acute lymphocytic leukemia (ALL), primarily owing to the development of targeted…
Date: 1st September 2021
Texas MPN Workshop 2021: updates on interferons for MPNs
Many clinical trials are currently investigating the potential benefits of interferons in the treatment of myeloproliferative neoplasms (MPNs), in particular…
Date: 27th August 2021
EHA 2021: real-world data on myeloma, lymphoma and CLL
Real-world data gained through scientific studies is essential in the advancement of treatments for all hematological malignancies. Historically, pharmaceutical companies…
Date: 25th August 2021
Novel BTK inhibitors for NHL
Over the past two decades the treatment landscape for non-Hodgkin lymphoma (NHL) has rapidly evolved, with the development of Bruton’s…
Date: 19th August 2021
Latest updates on T-cell therapies for non-Hodgkin lymphoma
Research into the treatment of non-Hodgkin lymphoma (NHL) has made great progress within the last decade, with clinical trials such…
Date: 18th August 2021
Novel CD20/CD3 bispecific antibodies in NHL
Immunotherapies are showing increasingly promising results for the treatment of patients with non-Hodgkin lymphoma (NHL) and, in particular, bispecific antibodies…
Date: 17th August 2021
Latest updates on CAR-T therapy for lymphoma
At present, four types of chimeric antigen receptor T-cell (CAR-T) therapy are FDA approved for specific types of lymphoma: for…
Date: 16th August 2021
EHA & ICML 2021: updates in Hodgkin lymphoma
Although classical Hodgkin lymphoma has a high cure and overall survival rate, the treatment of relapsed/refractory disease, treatment-related adverse events,…
Date: 6th August 2021
Latest transplant updates from EHA 2021
Hematopoietic stem cell transplantation (HSCT) is used as a treatment option for a wide variety of hematological disorders. Graft-versus-host disease…
Date: 4th August 2021
Key updates on CAR-T therapy for multiple myeloma
The treatment of multiple myeloma is a rapidly evolving field with advances in the understanding of myeloma disease biology contributing…
Date: 2nd August 2021
The Lymphoma Sessions: highlights from EHA and ICML 2021
In this roundtable discussion, chaired by Gilles Salles, MD, PhD, Memorial Sloan Kettering, New York, NY; Nirav N. Shah, MD,…
Date: 30th July 2021
The CLL Sessions: highlights from EHA and ICML 2021
In this roundtable discussion, chaired by Paolo Ghia, MD, PhD, Università Vita-Salute San Raffaele, Milan, Italy; Susan O’Brien, MD, University…
Date: 27th July 2021
EHA 2021: updates on treatment for MDS
Myelodysplastic syndromes (MDS) are a group of myeloid clonal disorders caused by a defect in bone marrow, which hinders their…
Date: 26th July 2021
iwNHL 2021: immunotherapy and the microenvironment
Recent progress in the field of immunotherapy presents an exciting alternative to standard chemotherapy treatments for patients with non-Hodgkin lymphoma….
Date: 23rd July 2021
The Myeloma Sessions: key highlights from EHA and ASCO 2021
The introduction of many novel drug classes and therapies has resulted in significant improvements in overall survival outcomes for patients…
Date: 21st July 2021
EHA 2021: key trial updates in myelofibrosis
The breakthrough discovery of upregulation of the JAK-STAT signaling pathway as the driving force behind myeloproliferative neoplasms (MPNs) has led…
Date: 20th July 2021
The MPN Sessions: highlights from EHA and ASCO 2021
Over the past decade there has been a vast increase in the number of clinical trials taking place in the…
Date: 16th July 2021
The MDS Sessions: highlights from ASCO/EHA 2021
Treatment options for patients with myelodysplastic syndromes (MDS) remain limited, with the rapid advances seen in other hematological malignancies not…
Date: 8th July 2021
EHA 2021: fixed-duration therapies and sequencing in CLL
Over the last years, the chronic lymphocytic leukemia (CLL) field has seen significant growth in new drugs and new treatment…
Date: 8th July 2021
The AML Sessions: Highlights from ASCO/EHA 2021
Acute myeloid leukemia (AML) is a clonal hematologic malignancy defined by genetic heterogeneity due to recurrent gene mutations. Precision medicine…
Date: 7th July 2021
EHA 2021: key trial updates in myeloma
The treatment and management of multiple myeloma has evolved drastically over the last ten years with the introduction of many…
Date: 7th July 2021
Key updates on CAR-T therapy for ALL
There are several forms of acute lymphoblastic leukemia (ALL), with B-cell ALL being the most common (around 75% of cases)….
Date: 5th July 2021
The Myeloma Sessions: post-COMy 2021 myeloma patients session
During the COVID-19 pandemic, myeloma support and advocacy groups were forced to adapt to a new way of working in…
Date: 28th June 2021
EHA 2021: MRD in myeloma
Over the past ten years, the approval of several new and effective therapies for multiple myeloma has significantly improved overall…
Date: 25th June 2021
Latest updates on CAR-T therapy for CLL
Chronic lymphocytic leukemia (CLL) is slow to develop and can be hard to treat as patients relapse or become refractory…
Date: 16th June 2021
The Myeloma Sessions: post-COMy 2021 roundtable
Age is an important prognostic factor in multiple myeloma, with patients aged over 75 years showing inferior outcomes when compared…
Date: 3rd June 2021
Focus on ALL: treating older patients, Ph-like ALL & post-transplant interventions
Advances in both the treatment landscape and the pathology of the disease have improved the outcome of children and adults…
Date: 28th May 2021
MDS Session: Women in Science
Myelodysplastic syndromes (MDS) are a heterogenous group of myeloid disorders characterized by the accumulation of dysplastic cells within the bone…
Date: 17th May 2021
Key updates on CAR-T & cellular therapy for AML
Acute myeloid leukemia (AML) is the most common type of leukemia in adults and is highly heterogenous. AML is typically…
Date: 17th May 2021
The MDS Sessions: highlights from ASH 2020
Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid disorders characterized by the accumulation of dysplastic cells within the bone…
Date: 27th April 2021
The Transplant Sessions: ASH 2020 highlights
The management of post-transplantation relapse and immune attack is an ongoing battle in patients undergoing bone marrow transplants. The efficacy…
Date: 23rd April 2021
The Lymphoma Sessions: ASH 2020 highlights
The treatment of aggressive lymphomas such as diffuse large B-cell has seen dramatic changes, and with the advent of bispecific…
Date: 23rd April 2021
Latest updates in Hodgkin lymphoma from ISHL HL 2021
The International Symposium on Hodgkin Lymphoma (ISHL) 2021 Hodgkin Lymphoma (HL) update gathered an international panel to discuss the most…
Date: 20th April 2021
The Myeloma Sessions: Post-ASH 2020 UK Discussion
The development of immunomodulatory agents and proteasome inhibitors alongside stem cell transplantation and chemotherapy has significantly improved the treatment options…
Date: 19th April 2021
The Post-EBMT for Trainees VJSessions
The European Group for Blood and Marrow Transplantation (EBMT) Trainee Committee was established in 2021 to address the needs of…
Date: 15th April 2021
Post-ASH Amyloidosis Session from VJHemOnc
The most common form of amyloidosis, light-chain (AL) amyloidosis, results from abnormalities in plasma cells causing them to produce abnormal…
Date: 13th April 2021
The Post-EBMT VJSessions from VJHemOnc
The 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) was held virtually this year and…
Date: 7th April 2021
Post-EBMT highlights in acute myeloid leukemia
Acute myeloid leukemia (AML) is the most common type of adult leukemia, with over 19,500 new cases estimated to be…
Date: 6th April 2021
The CLL Sessions: highlights from ASH 2020
Chronic lymphocytic leukemia (CLL), also known as B-cell CLL (B-CLL) is the most common leukemia in Europe and North America….
Date: 17th March 2021
The Lymphoma Sessions: highlights from ASH 2020
Lymphoma is a collection of cancers which develop in the lymphatic system and affect the lymphocytes. The risk factors for…
Date: 17th March 2021
The MDS Sessions: Giants in MDS
The diagnosis and treatment of myelodysplastic syndromes (MDS) has moved on dramatically in the few three decades. From across the…
Date: 17th March 2021
Latest therapies in AML: IMGN632, magrolimab & gilteritinib
The armamentarium of therapeutic modalities in acute myeloid leukemia (AML) has taken several strides in the last few years as…
Date: 16th March 2021
VJSession: EBMT/EHA CAR-T Nursing Session
The 3rd European CAR T-cell Meeting, organized by the European Society for Blood and Marrow Transplantation (EBMT), and the European…
Date: 23rd February 2021
The Myeloma Sessions: key updates from ASH 2020
Over the last decades, a deeper understanding of multiple myeloma’s complex pathobiology has transformed the diagnosis, prognosis, and treatment paradigm,…
Date: 22nd February 2021
The MPN Sessions: Rapidly advancing genomic discoveries and treatment strategies in MPNs
Mechanistically, myeloproliferative neoplasms (MPNs), comprising primary myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET), were a mystery for many…
Date: 19th February 2021
Updates for the management of MDS from ASH 2020
During the 62nd American Society of Hematology (ASH) 2020 Annual Meeting and Exposition, several abstracts provided important updates for the…
Date: 16th February 2021
The AML Sessions: highlights from ASH 2020
Improved understanding around the pathophysiology and heterogeneity of acute myeloid leukemia (AML) has led to a rapidly evolving treatment paradigm…
Date: 16th February 2021
The MDS Sessions: treating MDS around the world
The epidemiology, diagnosis and treatment of myelodysplastic syndromes (MDS) varies across the globe. In resource-limited countries, the diagnosis of MDS…
Date: 12th February 2021
Advances in the amyloidosis space: Prognostic factors, CAEL-101 immunotherapy and real-world data
Amyloidosis is the name attributed to a group of diseases caused by the extracellular accumulation of amyloid, an abnormal, insoluble…
Date: 5th February 2021
Developments in CLL: MRD, LOXO-305 and venetoclax at ASH 2020
Chronic Lymphocytic Leukemia (CLL) is a B-cell malignancy, predominantly affecting the elderly, which is characterized by an accumulation of immunologically…
Date: 28th January 2021
Myeloma at ASH 2020: talquetemab, CARTITUDE-1 & highlights
The field of multiple myeloma is rapidly evolving and can be credited to an increased understanding of the biology of…
Date: 20th January 2021
Advances in CAR T-cell therapies for lymphoma from ASH 2020
Lymphoma is a group of malignant neoplasms of lymphocytes that progress in the lymphatic system. Generally, lymphomas are categorized into…
Date: 18th January 2021
Moving forward in MPN: timing driver mutations and novel therapies from ASH 2020
Myeloproliferative neoplasms (MPNs) are a heterogeneous group of rare myeloid neoplasms characterized by the abnormal proliferation of hematopoietic stem cells…
Date: 11th January 2021
The MDS sessions: lower-risk disease
Myelodysplastic syndromes (MDS) represent a range of disorders characterized by morphologic dysplasia, cytopenias, and a risk of progression to acute…
Date: 7th December 2020
The AML Sessions: FLT3-mutated disease
Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are seen in 30% of all acute myeloid leukemia (AML) cases,…
Date: 27th November 2020
The Lymphoma Sessions: highlights from iwNHL 2020
This year’s virtual International Workshop on Non-Hodgkin Lymphoma (iwNHL) highlighted key progress in our understanding of various non-Hodgkin lymphoma (NHL)…
Date: 18th November 2020
The MDS sessions: clinical trial participation, endpoints & approvals
Myelodysplastic syndromes (MDS) represent a range of disorders characterized by morphologic dysplasia, cytopenias, and a risk of progression to acute…
Date: 17th November 2020
The AML Sessions: Venetoclax-based regimens
The BCL-2 inhibitor venetoclax has been evaluated in many hematological malignancies, including acute myeloid leukemia (AML). More recently, emerging mechanisms…
Date: 12th November 2020
The AML Sessions: IDH inhibitors
IDH mutations are present in 20% of acute myeloid leukemia (AML) patients and the use of IDH-targeting agents has shown…
Date: 3rd November 2020
The AML Sessions: Immunotherapy
Acute myeloid leukemia (AML) has seen rapid progression in the field of immuno-oncology which has led to vast improvements in…
Date: 8th October 2020
Advances in CAR-T and cellular therapy from EBMT 2020: MSCs, clinical trial updates and gene-edited effector cells
Cell therapy involves the transplantation of viable cells into a patient in order to trigger a medicinal effect. CAR-T is…
Date: 1st October 2020
SOHO 2020: Next questions in hematological malignancies
The Society of Hematologic Oncology (SOHO) 2020 Virtual Annual Meeting brought together global leading experts in hematological oncology who updated…
Date: 25th September 2020
The MPN Sessions: pathobiology, therapeutic strategies & clinical trials
Myeloproliferative neoplasms (MPNs) are a group of hematopoietic stem cell diseases characterized by the excessive production of one or more…
Date: 15th September 2020
Latest AML therapies: novel preparations and first in class agents
Acute myeloid leukemia (AML) is the most common type of acute leukemia among adults with almost 20,000 new cases reported…
Date: 14th September 2020
Advances in the lymphoma space: targeted therapies, PET-guided omission of RT and CAR T-cells
Lymphoma encompasses a wide selection of cancers that progress in the lymphatic system. Broadly, two types of lymphoma exist, non-Hodgkin…
Date: 10th September 2020
CLL: MRD and first-in class agents
Chronic lymphocytic leukemia (CLL) is a disorder characterized by morphologically mature but immunologically less mature lymphocytes, which accumulate in the…
Date: 13th August 2020
The Myeloma Sessions: Evolving management of myeloma & COVID-19
Patients with cancer frequently exhibit poorer post-COVID-19 infection outcomes, therefore the management of patients with hematological malignancies remains of high…
Date: 6th August 2020
MPNs highlights at EHA 2020: clinical trials, novel therapies & pitfalls
It is an exciting time in terms of therapeutic progress for myeloproliferative neoplasms (MPN). In recent years, there have been…
Date: 6th August 2020
The CLL Sessions: frontline therapy, BTK inhibitors, MRD negativity & novel therapies
A remarkable increase in the understanding of the pathogenesis of chronic lymphocytic leukemia (CLL) has led to the development of…
Date: 31st July 2020
The HemOnc & COVID-19 Sessions: treating hematological malignancies, reducing nosocomial COVID-19 infections, clinical trial participation and resource allocation
The ongoing COVID-19 pandemic caused by SARS-CoV-2 is an international public health issue and patients with cancer consistently demonstrate poorer…
Date: 28th July 2020
The AML Sessions: emerging immunotherapies, venetoclax-based regimens and targeted therapies in AML
The acute myeloid leukemia (AML) field has witnessed rapid evolution of late, with exciting developments in strategies for the treatment…
Date: 16th July 2020
Key updates in ALL at EHA 2020
Acute lymphoblastic leukemia (ALL) is a malignant disorder of lymphoid progenitor cells affecting both adults and children. With a greater…
Date: 7th July 2020
The Myeloma Sessions: smoldering myeloma, MRD evaluation, R/R disease & transplant-eligible patients
The multiple myeloma field is rapidly evolving, with exciting developments in strategies for the treatment of smoldering myeloma, relapsed/refractory (R/R)…
Date: 3rd July 2020
Systemic mastocytosis: current landscape, novel agents and COVID-19
Systemic mastocytosis (SM) is a rare hematological neoplasm. Advanced systemic mastocytosis can be sub-classified into either aggressive SM, SM with…
Date: 2nd June 2020
MRD assessment in AML: incorporation into clinical practice
Assessment of treatment efficacy in acute myeloid leukemia (AML) is highly relevant for further treatment stratification. In clinical trials, measurable…
Date: 22nd April 2020
Myeloma management in the COVID-19 era
The management of multiple myeloma presents many clinical challenges. The additional layer of complication COVID-19 places on patients and clinicians…
Date: 14th April 2020
CAR-T in the CLL space
Novel combinations work well for many patients suffering from chronic lymphocytic leukemia (CLL), but there is a subset of patients…
Date: 2nd April 2020
CAR T-cell therapy & multiple myeloma: past, present & future
CAR-T cell therapy offers a potentially paradigm-changing new treatment for multiple myeloma. Additionally, CAR-T toxicity is may be more manageable…
Date: 2nd April 2020
Harnessing the tumor microenvironment in lymphoma therapy
A deeper understanding of the characteristics, features and interactions at play in the tumor microenvironment has given great insight into…
Date: 2nd April 2020
CLL therapy: the latest trial updates and innovative novel therapies for the future
Recent clinical trials studying novel therapeutic strategies to target chronic lymphocytic leukemia (CLL) have brought a spotlight to their potential…
Date: 20th September 2019
Precision epigenetic therapy for B-cell lymphoma
Despite marked progress in the lymphoma treatment landscape, the prognosis of patients with relapsed and/or refractory disease remains poor; thus,…
Date: 18th July 2019
Induction therapy in myeloma: an ever-changing paradigm
In the majority of hematologic malignancies, induction treatment is given to achieve complete remission. In multiple myeloma, this has only…
Date: 18th July 2019
iwAL 2019: looking to the future of acute leukemia therapy
The treatment landscape of acute myeloid and lymphoblastic leukemia continues to evolve with the addition of novel therapies and methods…
Date: 6th June 2019
Acute leukemia: pushing boundaries in disease management
This is an exciting time in the acute leukemia field, with advances in both the treatment landscape and the pathology…
Date: 6th June 2019
CAR T-cell therapy and precision medicine in non-Hodgkin lymphoma
Precision medicine provides an array of benefits for the treatment of non-Hodgkin lymphoma patients, but it also has its challenges….
Date: 18th December 2018
MRD testing in multiple myeloma: new technology with promising clinical applications
Determining measurable residual disease (MRD) status is undoubtedly proving to be an effective method of prognostication and measurement of response…
Date: 23rd November 2018
CAR T-cells in myeloma: exploratory targets, payment models & treatment sequence
CAR T-cell therapy presents the opportunity to completely revolutionize the treatment of multiple myeloma, with research currently exploring the optimal…
Date: 11th October 2018
Patient discussion at EHA 2018: CAR T-cells and MRD in CLL
CAR T-cells have demonstrated impressive efficacy in a variety of hematological malignancies, but their use in chronic lymphocytic leukemia (CLL)…
Date: 14th September 2018
CLL therapies today: novel agents, combinations & the future of the field
Chronic lymphocytic leukemia (CLL) is experiencing a revolution in its treatment approaches. New therapies are constantly in development, and the…
Date: 20th August 2018
CAR T-cell therapy: where are we now and what’s in store for the future?
Over the last several years, CAR T-cell therapy has emerged as a revolution in immunotherapy, with incredible results to date….
Date: 25th July 2018
Focus on MRD: current landscape and future questions in hemonc
Measurable residual disease (MRD) has been a hot topic of interest due to its potential applications in the clinical setting….
Date: 4th July 2018
Acute leukemias discussion: what does genomics and epigenomics tell us about patient management?
A stimulating session on the implications of genomic data for the management of acute myeloid leukemia (AML) and acute lymphoblastic…
Date: 16th March 2018
Acute leukemias: is MRD already a surrogate for survival?
The use of minimal residual disease (MRD) in the management of acute leukemias is a hotly debated topic. Despite the…
Date: 9th March 2018
Revolutionary immunotherapies for lymphoma
Immunotherapy has emerged in recent years as an effective novel treatment for lymphoma, with studies constantly striving to identify new…
Date: 2nd February 2018
Latest advances and current challenges in immunotherapies for lymphoma
In this lively discussion, Catherine Bollard, MBChB, MD, FRACP, FRCPA, from the Children’s National Health System and George Washington University,…
Date: 15th December 2017
The circle of CLL: from gene discovery to targeted treatment
In this exciting feature, Carlo Croce, MD, from Ohio State University, Columbus, OH, provides an overview of the history of…
Date: 8th December 2017
Myeloma 2017 day 2 highlights: MRD, targeted therapies and imaging advances
This is a very exciting time for multiple myeloma (MM) research, with advances in a range of areas from new…
Date: 16th November 2017
Myeloma 2017 day 1 highlights: immunotherapy advances, a new MM subtype and liquid biopsies
Fantastic advances in immunotherapy, including CAR T-cells, bispecific antibodies and potential immunotherapy combinations, were presented at the Myeloma 2017 meeting…
Date: 16th November 2017
Debate on the use of MRD for multiple myeloma management
The highly anticipated panel discussion on the hot topic of MRD at the Myeloma 2017 meeting in Edinburgh, UK produced…
Date: 16th November 2017
